A mutational analysis of the hinge region of the N-lobe of lactoferrin : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University by Shewry, Steven Christopher
Copyright is owned by the Author of the thesis.  Permission is given for 
a copy to be downloaded by an individual for the purpose of research and 
private study only.  The thesis may not be reproduced elsewhere without 
the permission of the Author. 
 
A mutational analysis of the hinge region of the 
N-lobe of lactoferrin. 
A thesis presented in partial fulfilment of the requirements for the degree of 
Master in Science in Biochemistry at Massey University. 
Steven Christopher Shewry 
1996 
11 
ABSTRACT 
Lactoferrin is an 80kDa iron binding glycoprotein that is found as a major 
component of human milk , as well as in many other exocrine solutions. Lactoferrin 
binds reversibly, and with high affinity, 2 Fe3+ ions with 2 synergistic CO32- ions. The 
crystal structure shows that the polypeptide chain is folded into two similar lobes, each 
binding one Fe3+ and CQ32- ion. In the metal free state, the N-terminal lobe has been 
found to adopt an open structure, with rotation occurring around two residues found in 
separate beta strands located at the back of the binding site in a region referred to as the 
hinge. A sequence alignment of these two strands over the greater transferrin family 
shows a very high level of conservation panicularly of the two residues at the centre of 
this rotation (Pro 251 and Thr 90). 
The N-terrninal half of human lactoferrin (LfN) has been constructed, expressed 
and the crystal strncture determined. 
In an attempt to understand the importance of the conservation of these two 
residues , and their effect on binding , a mutational analysis was initiated. 
Oligonucleotide site-directed mutagenesis has been used to construct mutants in the 
cDNA encoding for human lactoferrin using the M13 bacteriophage. The mutant cDNA 
was transformed into a mammalian expression vector (pNUT). After transfection of the 
pNUT vector into baby hamster kidney cells (BHK), the mutant proteins were 
expressed and purified from the culture medium using a CM-sephadex ion-exchange 
column. 
Absorption maxima and pH-dependent iron-release experiments were carried 
out on the mutants. The data shows that the mutants behave essentially the same as 
LfN, the exception being P251G which appears to release the iron over a shoner pH 
range. The reason for this is not yet fully understood. 
The crystal structure of P251 A in the iron-bound form was solved by molecular 
replacement using the structure of LfN as the starting model. The structure of P251A 
was refined using data between 20.0 and 2.0 A. The current model has good geometry 
and has an R-factor of 18.6 %. Analysis of the structure shows that it is essentially 
identical to that of the LfN structure. 
Although the strncture of the iron-free form has not been determined, it appears 
that changes to the hinge region of the N-lobe of lactoferrin do not affect the iron-
binding or structural characteristics of the protein. 
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A. INTRODUCTION 
A.1. Introduction. 
For all plants and animals, and for virtually all microbes, life without iron is 
impossible. In the cell, where essential iron-containing enzymes and proteins are found 
in species ranging from bacteria to man, the thermodynamically stable form of iron is 
Fe(TII). Free Fe3+ is, however, rapidly hydrolysed in solution to form the insoluble 
Fe(OH)3 complex. This insolubility problem is overcome by proteins involved in 
storage and transport of iron. 
Transferrin is the name given to the family of proteins involved in the 
solubilisation, sequestration, and transport of ferric iron. The roles of transferrins in 
general is coupled to their tight binding of Fe3+. These roles involve controlling the 
levels of free iron in body fluids, preventing precipitation of Fe(OH)3 by keeping the 
concentration of free Fe3+ at less than IQ-18 M, and preventing free radical damage 
(free radical production is catalysed by free iron). The name "Transferrin" is taken 
literally to mean "transport of iron" (Baker, 1994) and the transferrin family includes at 
least four iron-binding proteins, serum transferrin, ovotransferrin, lactoferrin, and 
melanotransferrin. Serum transferrin is the iron transport protein found in the blood of 
vertebrates and some invertebrates. Ovotransferrin, found in the white of eggs, is 
identical to the serum transferrin of birds except in the carbohydrate moiety attached to 
the protein (Thibodeau et al, 1978). Melanotransferrin is a membrane-associated protein 
found on all cells, but expressed at high levels on melanoma cells (Rose et al, 1986). 
Lactoferrin, the subject of this study, is the iron-binding protein most commonly found 
in milk, but also in other exocrine secretions including tears, saliva, seminal fluid, 
cervical mucous, gastric fluid, nasal exudate, bronchial mucous, and hepatic bile 
(Masson et al, 1969; Weinburg, 1984). Lactoferrin is also found in the specific granules 
of mature neutrophils (Baggolini et al, 1970). 
The transferrins are glycoproteins with a molecular weight of about 78,000 Da. 
The number and positioning of the carbohydrate chains differs from one transferrin to 
another. For example, human serum transferrin has two chains attached to the C-lobe of 
the molecule, while human lactoferrin also has two chains, but one attached to each of 
the lobes. 
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Melanotransferrin has additional amino acids on the C terminal end of the 
molecule thought to be involved in anchoring the protein to the cell membrane (Rose er 
al, 1986), and responsible in part for its higher molecular weight of 97,000 Da. Other 
transferrins of differing size are the crab serum transferrin (Cancer magister) with a 
molecular weight of about 150,000 Da, and the transferrin of Pyura stolonifera with a 
molecular weight of about 40,000 Da (Baker, 1994). 
The transferrins are generally folded into two lobes each of which reversibly 
binds a ferric ion concomitantly with a bicarbonate anion. Two members of the family, 
however, melanotransferrin and the transferrin of the homworm (Manduca sexta), bind 
only one ferric ion (Baker, 1994) as a result of amino acid sequence changes in one of 
the two binding sites. Apart from these, the metal and anion-binding amino acid 
residues are identical in both lobes of the transferrins, and are conserved in all members 
of the transferrin family. 
Lactoferrin is found in the milk of some, but not all, species, being completely 
absent in the milk of the rat, rabbit and dog. The milk of the rat and rabbit contains 
significant levels of transf errin, while the milk of the dog contains neither protein 
(Masson and Heremans, 1971 ). Lactoferrin levels are highest in slow-growing species 
such as the human and guinea pig, and are low or absent in fast-growing species such as 
rabbits, rats and cattle (Weinburg, 1984). Lactoferrin expression also varies during 
lactation and this suggests that the gene is hormonally regulated. This is supported by 
the work of Pentecost and Teng (1982), who found that the major oestrogen-stimulated 
protein synthesised in the uterine tissue of the mouse is lactoferrin. 
A.2 . Biolo~ical roles of lactoferrin 
For many years, a considerable amount of effort has been directed at 
determining the biological role(s) of lactoferrin. Many different roles have been 
postulated, but as yet, no single, primary one has been identified. Among those that 
have been suggested are (i) iron-withholding in order to starve potential pathogens of 
iron, (ii) a bactericidal function, (iii) binding to receptors in order to perform various 
functions, (iv) modulation of the inflammatory response, (v) acting as a growth 
promoter, and (vi) as a source of iron for nutritional reasons. 
Many other functions have been associated with lactoferrin, but the evidence is 
somewhat dubious. The following are the most widely accepted potential functions. 
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A.2.1. Iron withholding. 
The egg is a good example of iron-withholding defence. The developing embryo 
is provided with a large amount of iron ( 1 µg in the egg yolk) for use in DNA synthesis, 
electron transport, and other important fonctions, while a porous shell is needed in order 
for air to be available. This porous shell, however, allows microbial invaders to enter 
the egg, and this problem of microbial invasion is overcome by placing no iron (an 
essential element for bacteria) in the egg white, while also including a powerful iron-
binding protein. This iron-binding protein was discovered by Osborne and Campbell 
(1900), and is called ovotransferrin. 
Schade and Caroline (1944) demonstrated that of the 10 vitamins and 31 
elements tested, only iron overcame the bacteriostatic activity of egg white. The 
bacteriostatic factor (ovotransferrin) suppressed activity of gram negative bacteria, 
gram positive bacteria, and also fungi. Alexander in 1948 discovered that babies that 
were breast fed suffered less severe cases of gastric enteritis than did bottle fed babies. 
A factor in human milk was therefore responsible for this reduced level of infection. It 
was later discovered (Bullen et al, 1972) that samples of milk with unsaturated iron-
binding capacities had a powerful bacteriostatic effect on E.coli 0111/B4. This effect 
was abolished if the proteins involved were saturated with iron. 
In vivo work (Murray et al, 1978) shows that iron indeed enhances the incidence 
of infection. Somali nomads have a high incidence of iron deficiency, due to their all-
milk diet, and also show a low level of intestinal parasites. Murray et al fed the nomads 
daily for 30 days, either with placebo (aluminium hydroxide) as a control, or with iron 
(900 mg FeSO4). The subjects were observed for fever above 38°C and symptoms of 
infection. 7 /67 of the placebo group and 36n 1 of the iron group suffered infections, 
suggesting that the host defence against these infections was better with an iron 
deficiency than with iron present. 
The factor accounting for these observations (lactoferrin), was discovered, 
purified and studied around 1960 (Johansson, 1960) An antibacterial role for lactoferrin 
involving iron sequestering is also supported indirectly by the observation that both 
human and bovine lactof errin are secreted in the apo form (Lonnerdal, 1985). 
It seems that vertebrate hosts inhibit microbial growth by withholding iron, and 
do so by the use of proteins of the transferrin family, serum transferrin, ovotransferrin, 
and lactoferrin. 
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A.2.2. Bactericidal activity. 
Although the bacteriostatic activity of lactoferrin, based on iron sequestering, 
appeared well established, Arnold et al ( 1977) demonstrated that in some cases this 
activity was not reversed by the addition of iron. This pointed to an alternative 
mechanism that could be involved in some cases. In this work, immunofluorescence 
studies showed apolactoferrin binding to the surface of susceptible bacteria. A possible 
explanation for this was that inhibition was due to lactoferrin blocking sites that were 
required for the transport of an essential nutrient. ff this was so, then inhibition should 
be reversed by the removal of any surface lactoferrin, and any lactoferrin-inhibited cells 
should then be able to continue to grow. Arnold et al (1982) removed the lactoferrin by 
techniques that retained the viability of control bacteria. The experimental bacteria 
(Streptococcus mutans) however failed to regain viability upon treatment to remove the 
lactoferrin. In effect, it showed the irreversible bactericidal effect of lactoferrin upon 
S.mutans. Other supporting evidence comes from Valenti et al (1985 and 1987) who 
showed, by use of a dialysis membrane, that the lactoferrin needed to be in direct 
contact with the bacterial surface to exert its bactericidal effect. 
In a recent report (Tomita et al, 1994), lactoferrin was found to agglutinate the 
protoplasts of Micrococcus lutens. This agglutination was lost by chemical modification 
of the basic residues of lactoferrin, indicating that electrostatic action is involved. Using 
phase contrast microscopy, and spectroscopy, Tomita et al, (1994) found that both the 
apo and iron loaded forms of lactoferrin inhibited the growth of the bacteria. This points 
to an antibacterial mechanism in addition to the iron witholding bacteriostatic 
mechanism, as the latter should be effective only with the apo form of lactoferrin. 
Ovotransferrin and human transferrin had no effect and it was concluded that the 
cationic charge from lysine or arginine residues in lactoferrin are needed to agglutinate 
the bacterial cells. 
Bactericidal activity is also found in proteolytically-derived and synthetic 
cationic peptides corresponding to the N terminal regions of lactoferrin (Bellamy et al, 
1992). The precise bactericidal mechanism remains unclear. It may involve direct 
interruption of the membrane by this region, or the blocking of essential receptors on 
the bacterial outer membrane surf ace. 
To understand the mechanism of action of one of these peptides, Bellamy et al, 
(1993) investigated the cell binding properties of lactoferricin B (a peptide 
corresponding to the N terminal 25 amino acids of bovine lactoferrin) with both gram 
positive (Bacillus subtilis) and gram negative (E.coli) bacteria, and compared these 
properties with the rate of irreversible death of these cells. Lactoferricin B is highly 
cationic with 8/25 basic residues. Other antimicrobial peptides with similar cationic 
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features include magainins from frog skin; cecropins from the haemolymph of insects; 
and defensins from mammalian neutrophils (Westerhoff et al, 1989), (Hill et al, 1991). 
14C-labelled lactoferricin B bound to the cell surface of both gram negative and 
gram positive bacteria and the rate of binding was consistent with the rapid rate of 
killing observed. Cell-binding activity was pH dependent implying that the cationic 
property of the peptide was important. The optimum pH however was dependent on the 
particular bacterial strain (pH 6.0 for E.coli, pH 7.5 for B.subtilis). With each strain, the 
killing effect was maximum near the optimum pH for cell binding implying that the 
bactericidal effect of lactoferricin B is dependent upon cell binding. This reflects the 
earlier work by Valenti et al (1987) with lactoferrin. 
Naidu et al (1993) generated a peptide from lactoferrin by pepsin hydrolysis. 
This also showed antimicrobial activity, but failed to inhibit 1251-1abelled lactoferrin 
from binding to E.Coli and 10 other species of the Enterobacteriaceae. This indicated 
that lactoferrin and this peptide may bind by different mechanisms, and cast some doubt 
on the relevance of peptides in elucidating the function of lactoferrin. 
An interesting twist to this bacteriostatic/bactericidal role is the work by Yu and 
Schryvers (1993) showing that some pathogenic bacteria (Neisseria meningitidis, 
N.gonorrhoeae, and Moraxella catarrhalis) may work by inhibiting lactoferrin and 
transferrin. They found by SOS PAGE that these bacteria bound lactoferrin to their 
membrane, and that the receptors that bound human lactoferrin were different from the 
ones that bound human transf errin. They propose that these bacteria bind lactoferrin in 
order to acquire iron from it, therefore overcoming its bacteriostatic effect. It does not 
rule out, however, a defensive role against the bactericidal effect of lactoferrin. 
A.2.3. Receptor binding. 
One of the intriguing characteristics of lactoferrin is its ability to bind to a wide 
variety of cell types. Several researchers have investigated this binding, and have 
related it to possible functions for lactoferrin. 
A putative intestinal receptor for lactoferrin in humans was initially proposed by 
Cox et al (1979) and was isolated from rabbit brush border cells in 1989 (Mazurier et 
al, 1989). This receptor was found to be a 100 kDa protein. 
Lactoferrin has also been found to bind to the brush border cells of rhesus 
monkeys (Davidsson and Lonnerdal, 1988) under conditions in which these cells can 
accumulate iron from lactof errin. Only human lactoferrin released its iron to these cells, 
bovine lactoferrin, human transf errin, and ovotransferrin having no such ability 
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(Davidsson and Lonnerdal, 1989). Lacroferrin receptors have also been reported in 
mouse small intestinal brush border cells (Hu er al, 1988). 
The binding constant and number of receptors per cell have been calculated for 
caco-2-cells, a human colon carcinoma cell line with characteristics of the brush border 
cells (Iyer et al, 1993). Human lacroferrin was labelled either with 59fe, or with 125r. 
The results showed that human lactoferrin in both forms bound to the receptor in a 
saturable manner. Scatchard analysis indicated that it was a single binding site with a 
Kd of 1.7 x 10-6, and about 6 x 105 binding sites per cell. At 370c, lactoferrin was 
taken up by the cell. 59fe taken up as 59fe-Lf was not transported across the 
monolayer, but when 125]-Lf was used, there was a continuous transport of 125! 
associated with a major protein later confirmed to be lactoferrin using gel 
electrophoresis and ELISA. In conclusion, Fe2Lf is taken up by the cell, iron is then 
released and used by the cell, and Lf in part is transported across the cell. 
This receptor has been cloned, sequenced and expressed in a baculovirus 
system, and confirmed to bind hLf by ligand blotting. The protein consists of 351 amino 
acids with four potential glycosylation sites. There is a strong hydrophobic region of 29 
amino acids possibly acting to anchor the receptor to the membrane (Iyer et al, 1994). 
Lactoferrin receptors have also been described in other cell types including 
lymphocytes, parenchyma liver cells, macrophages, and monocytes. With human 
peripheral lymphocytes, Mazurier et al ( I 989) found that in these cells during the 
resting state there were no lacroferrin receptors present. However upon stimulation by 
phyrohemagglutinin, lactoferrin receptors were visualised using 1251-labelled 
lactoferrin as a probe. The receptor gave rise to 2 bands of JOO and I JO kDa. 
A high affinity receptor has also been discovered in monocytes with a Kd of 1 
nM (Yuen et al, 1993). This work found that both monocytes and lymphocytes showed 
a dose dependent response in interleukin(lL)-1 B and IL-6 to increasing levels of 
lactoferrin. It appears that lacroferrin binds to these cells and this results in increased 
IL-lB and IL-6 levels. 
Mc Abee and Esbensen ( 1991) showed that hepatocytes also bind and internalise 
lactoferrin. 80% of the lactoferrin was internalised by these cells after 60 min at 37°C. 
The functional consequences of lactoferrin binding to these cells remains unclear, 
although lactoferrin has been found, in vitro and in vivo, to inhibit the binding and 
uptake of apoE-bearing lipoproteins by parenchyma liver cells (Huettinger et al, 1988; 
Van Dijk et al, 1991). Arginine residues in lactoferrin were shown to be crucial for 
recognition of lactoferrin by the liver cells (Ziere et al, 1992). More recent work by the 
same group (Ziere er al, 1993), showed, by removal of the first 14 amino acids, that it 
is the four arginine residues at the N terminus that are important. 
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As previously outlined, the pathogenic bacteria Neisseria meningitidis, 
N.gonorrhoeae, and Moraxella catarrhalis, overcome the iron sequestering effect of 
lactoferrin by using receptors in their membranes to bind the individual lobes of 
lactoferrin (Yu and Schryvers, 1993). In the same way, lactoferrin can also bind to 
certain bacteria from the Enterobacteriaceae family. Gado et al (1991) identified porins 
as the lactoferrin binding site on these bacteria. This binding was reversible and had a 
low affinity. Yu and Schryvers (1993) found that it was both the C- and N-lobes of 
lactoferrin that were responsible for binding to bacterial receptors. This contrasts with 
transferrin, in which the bacterial transferrin receptor only binds to the C-lobe of human 
transferrin (Alcantara et al, 1993). The region of human lactoferrin involved in binding 
to human lymphocytes however, has been localised to domain 1 of the N-lobe and there 
is no observable binding of the C-lobe (Rochard et al, 1989), (Legrand et al, 1992). 
This shows that the interaction with lactoferrin is different for mammalian receptors 
than for bacterial receptors. 
A.2.4. Inflammation. 
Another function proposed for lactoferrin is modulation of the inflammatory 
response. Lactoferrin is found in the specific granules of neutrophils (Baggiolini et al, 
1970), and during the inflammatory response, levels of lactoferrin in the granules 
decline, while plasma levels of lactoferrin increase (Malmquist et al, 1978). It seems 
that the neutrophils release the lactoferrin, although it is not known how this occurs. 
Boxer et al (1982), using immunohistological techniques, found that lactoferrin released 
from neutrophils bound to the polymorphonuclear (PMN) membrane and altered its 
surface properties by reducing the surface charge. Transferrin did not do this. This work 
correlates with the observation that during inflammation there is an increased adherence 
of the PMN cells to the endothelial cells which results in an amplification of the 
inflammatory response (Oseas et al, 1981). By binding to the PMN membrane, 
lactoferrin helps the PMN cells to adhere to the endothelial cells and therefore amplify 
the inflammatory response. 
The release of lactoferrin from neutrophils has also been suggested to have an 
antibacterial role (van Snick et al, 1974). It was proposed that lactoferrin released from 
the neutrophils bound free iron, possibly derived from transferrin, and once iron-
saturated, lactoferrin bound to macrophages which were then removed by the 
reticuloendothelial system. This bacteriostatic role of lactoferrin in neutrophils is 
supported by the finding that patients whose neutrophils lack the specific granules 
suffer from recurrent infections (Sanchez et al, 1992), but has been questioned by 
Baynes and Bezuida (1992) after they could not detect significant levels of lactoferrin 
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in the plasma. 
A.2.5. Growth factor activity. 
Transferrin is known to be involved in cell proliferation (Casey et al, 1989), and 
this raises the possibility that lactoferrin may also have a role in growth-promoting 
activity. This was proposed when human lactoferrin was found to stimulate the growth 
of all the human lymphoid cell lines tested, but not mouse lymphocyte cell lines, a 
human epithelial cell line, or a human fibroblast cell line (Hashizume et al, 1983). 
Human lactoferrin in the iron loaded form has also been found to stimulate the growth 
of phytohaemagglutinin-stimulated human peripheral blood lymphocytes. Moreover, 
receptors for lactoferrin appeared on the surf ace of these cells upon stimulation by 
phytohaemagglutinin (Mazurier et al, 1989). 
In addition to its possible growth-promoting activity, lactoferrin has also been 
shown to indirectly inhibit the growth of certain cell lines. Lactoferrin is responsible for 
regulating the proliferation of the granulocyte-macrophage progenitor cells by 
decreasing the production and release of a colony-stimulating activity found in 
macrophages (Broxmeyer et al 197 8) . Lactof errin is known to bind monocytes and 
macrophages, and this binding activity correlates with the inhibitory effect on these 
cells. 
A.2.6. Iron nutrition. 
Another suggested role for lactoferrin is in the uptake of iron for nutritional 
value. To perform this function, lactoferrin must be able to withstand proteolysis in the 
gastrointestinal tract, and evidence for this resistance was provided in the work of Spik 
et al (1982). A nutritional role for lactoferrin is also supported by the finding that 
receptors for lactoferrin have been identified in the small intestines of a variety of 
species (Iyer and Lonnerdal 1993). Lactoferrin binding then apparently leads to the 
retention of the iron by these cells (Iyer et al, 1993). 
This function is questioned by Davidsson et al (I 994) who separated out 
lactoferrin from human milk by treatment with heparin-sepharose, and then measured 
the incorporation of 58Fe into red blood cells 14 days after feeding infants aged 2-10 
months old. Their results showed that less 58Fe was incorporated into red blood cells 
with lactoferrin-containing milk, than with lactoferrin-deficient milk. 
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A.2.7. Other possible roles. 
As mentioned earlier, lactoferrin has many other postulated functions, one of 
which is to protect monocytes from oxidation (Brighton et al, 1991). It is proposed that 
lactoferrin binds to a receptor on the monocyte preventing hydroxyl damage to these 
and neighbouring cells. 
Whatever the function(s) of lactoferrin, it is generally accepted that most are 
linked in some way to the binding of iron. 
A.3. Structure of lactof errin. 
A.3.1. Primary structure. 
At the present time, the amino acid sequences of 17 proteins of the transferrin 
family have been determined either directly or from cDNA sequences. These are listed 
in Table A.1 . 
All the members of the transferrin family demonstrate a high degree of 
sequence similarity. This includes approximately 65% amino acid identity within the 
lactoferrins, and approximately 55% between the transferrins of higher animals and 
lactoferrin (Mead, 1992). The sequences of the insect transferrins and the membrane-
associated melanotransferrin are less conserved. Melanotransferrin has a 40% amino 
acid sequence identity with the mammalian transferrins, while the insect transferrins 
have 20 - 30% amino acid sequence identity with the higher transferrins (Baker, 1994). 
In addition to the amino acid sequences, the complete genomic DNA sequences 
for human transferrin (Schaeffer et al, 1987), chicken ovotransferrin (Jeltsch et al, 
1987), and mouse lactoferrin (Shirsat et al, 1992), have been reported. Comparisons of 
these sequences reveal that although the sizes of the genes vary, this is due to variation 
in the sizes of the introns and not the exons (coding regions). The positions of the 
intron/exon boundaries are conserved among transferrins. The position of one of the 
conserved exon/intron boundaries is between the N and C-lobes of the protein, 
supporting the theory of gene duplication put forth by Bowman and colleagues (1988). 
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Table. A.1. Primary sequences of the transfenin family known to date. 
Human Serotransf enin 
Horse Serotransferrin 
Pig Serotransfenin 
Rabbit Serotransferrin 
Rat Serotransferrin 
Xenopus Serotransf errin 
Human Lactoferrin 
Bovine Lactoferrin 
Goat Lactoferrin 
Mouse Lactofenin 
Pig Lactofernn 
Human Neutrophil Lactoferrin 
Human Melanotransferrin 
Chicken Ovotransferrin 
Atlantic Salmon Transferrin 
Homworm Transferrin 
Cockroach Transferrin 
Park et al, 1985, MacGillivray et al, 1983 
Caroenter er al, 1993; 
Baldwin and Weinstock, 1988 
Banfeld et al, 1991 
Schreiber er al, 1979 
Moskaitis et al, 1991 
Rado et al, 1987, Metz-Boutigue et al, 1984 
Mead and Tweedie, 1990 
Le Provost er al, 1994 
Pentecost and Teng, 1987 
Alexander et al, 1992 
Rado et al, 1987 
·------~ 
Rose et al, 1986 
Jeltsch and Chambon, 1982; Williams et al, 1982 
K vingedal er al, 1994 
Bartfeld and Law,1990 
J amroz er al, 1993 
A.3.2. Three-dimensional structure. 
A.3.2.1. Iron-loaded lacroferrin. 
The first crystallographic studies on transferrins date back more than 20 years 
(Magdoff-Fairchild and Low, 1970), and the first low resolution analysis of a transferrin 
was published in 1979 (Gorinsky et al, 1979). This involved rabbit serum transferrin, 
and demonstrated the bilobal nature of the molecule. 
In 1987, Anderson et al determined the structure of human lactoferrin at 3.2 A 
resolution and this structure was subsequently refined at 2.8 A resolution (Anderson et 
al, 1989). The polypeptide folding of this structure is shown in Fig A. I. 
Fig. A. l. Drawing crea ted by Ribbons (Richardson, 1985; Priestle, 1988) 
showing the structure of the full -length lac toferrin molecule with 
iron bound in both lobes. 
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The polypeptide chain is fol ded into two lobes, representing the N- and C-
terminal halves of the molecule (res idues 1-332 and 345-691 respectively). These are 
joined by a short, 3-turn, alpha heli x, (res idues 333-344) that consists largely of 
glutamyl, arginyl and alanyl residues. Both lobes have very similar polypeptide folding, 
consistent with their high level of amino acid sequence identity (about 40%), and each 
lobe contains a single iron-binding site. 
Inspection of the folding (Fig A. l ) shows that each lobe is further subdivided 
into two similar sized domain s (of about 160 res idues) , with a deep cleft between them, 
which houses the iron-bindin g site (Fi g A.2). The domain s in the N-lobe of human 
lactoferrin have been labelled Nl (res idues 1-90 and 252-332) and N2 (residues 91-
251), with the equivalent C-lobe domains being Cl (residues 345-433 and 596-691) and 
C2 (residues 434-595). 
Fig. A.2. Drawing created by Ribbon (Richardson, 1985; Priestle, 1988) 
showing the structureof the half-length lactoferrin molecule (LfN) 
with iron bound. The side chains for the ligands are included, as are the 
side chain of two residues of this study, Thr 90 and Pro 251. 
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The two iron-binding sites are extremely similar. In each case the iron atom is 
coordinated by four protein sidechains, 2 tyrosines, 1 hist idine, and 1 aspartate, coming 
from separate parts of the polypeptide chain. In the N-lobe these ligands are Asp 60, 
Tyr 92, Tyr 192, and His 253, wh ile in the C-lobe they are Asp 395, Tyr 435, Tyr 528, 
and His 597 . A unique feature of transferrins is that a carbonate (or bicarbonate) anion 
is bound with each metal ion, and neither metal ion nor anion is bound strongly by the 
protein in the absence of the other. The relationship is thus said to be synergistic. In the 
binding site the carbonate anion is found to bind to the metal in bidentate fashion, thus 
completing the metal coordination, and to also form a bridge between the metal ion and 
a positively charged region of the protein. The latter comprises an argin ine sidechain 
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(Arg 121 in the N-lobe, Arg 465 in the C-lobe) and the N terminus of an alpha helix, 
these being presented by one wall of the second domain (N2 or C2). The binding site is 
shown schematically in Fig A.3. 
Fig A.3. Schematic diagram of the metal and anion binding site in lactoferrin. 
Residue numbers are for the N-lobe (with the C-lobe given in brackets). 
(From Baker, (1994) with permission). 
With the knowledge of the lactoferrin structure, the structure of diferric rabbit 
serum transferrin has since been completed (Bailey et al, 1988). The overall folding 
pattern was similar to that of human lactoferrin, with similar domains, each based on a 
mixed beta sheet overlaid with alpha helices which pack against the two faces of the 
sheet. The main difference between the two structures was in the orientation of the two 
lobes. With the N-lobes superimposed, there is a 15 degree rotation of the C-lobe of 
transferrin compared to lactoferrin (Baker and Lindley ,1992). 
Despite observed differences in function between rabbit serum transferrin and 
human lactoferrin, the iron-binding sites are similar. If the atoms of the iron-binding 
site are superimposed, the root mean square deviation between atomic positions for all 
the combinations of the N and C-lobes is less than 0.6 A (Baker and Lindley, 1992). 
Therefore the functional differences between transferrin and lactoferrin are probably not 
concerned with the precise structure of the iron-binding sites. It has been suggested 
instead that the interactions between the two domains within a lobe may influence the 
functional differences between the transferrins and lactoferrins (Baker and Lindley, 
1992). 
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The carbohydrate chains on transferrins are all N-linked through asparagine 
residues. Glycosylation sites vary in number from one in rabbit serum transferrin and 
chicken ovotransferrin, to four in bovine lactofenin (human lactoferrin contains two 
sites). The sites are scattered over the surface of the molecule arguing against any direct 
functional role in iron-binding. The carbohydrate chains are heterogeneous with little 
defined structure observable by X-ray analysis. Except for certain species of fish (Tinca 
tinca and Ctenopharybgodan idella ), all known vertebrate transferrins are 
glycoproteins (Strati! et al, 1983). The absence of carbohydrate chains in these species 
suggests that they are not important in the physiological functions of the proteins. 
One intriguing question that has never been unequivocally answered is that of 
whether there is any biological advantage in having a bilobal molecule, with two iron 
sites. The bilobal structure has clearly arisen by gene duplication and fusion from a 
small ancestral protein of half the size (40kDa, a single lobe) with a single iron-binding 
site (Bowman et al, 1988). One possible explanation for the duplication has been 
advanced by Williams et al ( 1982) who found that isolated lobes of serum transferrin 
were rapidly lost from the bloodstream via the kidney. In this case only species that had 
evolved this bilobal form would have survived. Williams however proposes that a 
single lobed ancestor is unlikely, and instead, the ancestral protein may have been a 
bilobal form, or a membrane associated protein. An alternative possibility is that the 
two lobes have become differentiated in their properties (see later). 
A.32.2 . Apolactoferrin structure. 
A proper understanding of iron binding and release requires that the nature of the 
associated conformational changes be defined. Although X-ray analysis gives only a 
static picture, comparisons of the structures of iron-loaded and iron-free strucutres are 
an essential element in reaching such an understanding. 
The apolactoferrin structure was solved from protein in which the carbohydrate 
had been removed by enzymatic digestion using peptide N-glycosidase F (PGNaseF) 
and endoglycosidase F (Endo F), both isolated from Flavobacterium meningosepticum 
(Elder and Alexander, 1982). This deglycosylated protein had identical properties of 
iron-binding and release, and identical spectroscopic parameters to the native form. The 
crystals diffracted to 2.0 A resolution (Norris et al, 1989). The structure was determined 
by molecular replacement using diffractometer data to 2.8 A resolution, and refined to 
an R factor of 0.213 for data between 10 and 2.8 A. 
Fig. A.4. Superposition of the ope n and closed N-lobes in the 
full-length lactoferrin struc ture. 
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A strikin g feature of the X-ray analysis (Anderson et al, 1990), was the large 
conformational change seen for the -lobe of the molecule (Fig A.4). One domain ( 2) 
had rotated 54 degrees relative to the other domain (N l ), resulting in a wide-open 
binding cleft. The equivalent movement was not seen in the C-lobe, however. Both 
sites (N and C-lobes) had lost their Fe3+ ion . This one-open, one-closed structure was 
unexpected and two theories to explain this were proposed, (i) that extra constraints in 
the C-lobe (specifically a di su lphide bridge 483-677) inhibit opening of the C-lobe, and 
(ii) that an equilibrium exists between the open and closed forms in solution as seen for 
the periplasmic bindi ng proteins (PBP's) (Oh et al 1993). Crystal packing could then 
have selected the closed form of the iron-free state. If this is so, then the energy 
difference between the open and closed forms of the iron free protein must be small. 
This second explanation was confirmed, firstly by solution X-ray scattering 
measurement (Grossmann et al, 1992), and secondly when Faber et al (1995) solved the 
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structure of a second crystal from the apoprotein in which both sites were open (Fig 
A.5). The C-lobe only opens by about 15 degrees, probably due to the extra constraints 
present in the C-lobe. 
Fig. A.5 . Structure of full-length lactoferrin with both the N- and C- lobes open. 
In each lobe the conformational change that mediates the transition from closed 
to open form involves relative movement of the two domains. The axis of this 
movement is through a "hinge" in two backbone beta strands that connect the two 
domains and pass behind the iron-binding cleft (Fig A.6). The domains move as rigid 
bodies about this hinge, as is shown by superposi tion of the individual domains of 
Fe2Lf on those of apoLf. When this is done, therms deviation of the N2 domain (which 
rotates 54°) is only slightly greater that those for the other three domains (Anderson et 
al 1990); Nl, 0.52 A; N2, 0.65 A; Cl, 0.43A; C2, 0.44A. This means that the domain 
movement on iron release is a rigid body movement about a hinge. This rigid body 
movement for lac toferrin is the largest yet reported for any protein . 
In serum transferrins, lactoferrin s, and ovotransferrin, the C-lobe releases iron 
less readily, possibly due to its lesser flexibility, whereas in melanotransferrin and 
M.sexta transferrin, it does not bind iron at all. It may be that binding to the C-lobe has 
remained only in cases where a receptor mechanism exists to extract iron from the site 
and this idea again raises the quest ion of the biological importance of the bilobal 
structure. 
Fig A.6. Schematic diagram of the open (left) and closed (right) forms 
showing the action of the hinge in the N-lobe of lactoferrin. 
An arrow positions the part of the beta sheets involved in the 
"bending" of this region. 
A,4, Iron-binding properties. 
A.4.1. Introduction. 
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The orange-red color that develops when ferric iron is added to the transferrins 
is the main indicator of iron binding. The colour is due to an absorption band around 
460nm, although the precise Amax varies among the transferrins. In addition to this 
band, there is another specific absorption near 295nm (Aisen et al, 1969). 
One of the first studies to describe the iron-binding properties of lactoferrin was 
that of Aisen and Leibman (1972). These authors showed that the properties of 
transferrin and lactoferrin were very similar and suggested that the iron-binding ligands 
included 2 tyrosines and 1 nitrogen-containing amino acid, possibly histidine. These 
residues, and an additional aspartate residue, were confirmed when firstly the iron-
loaded human lactoferrin structure (Anderson et al, 1987), and secondly the iron-loaded 
rabbit transferrin structure (Bailey et al, 1988) were determined. 
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A.4.2. Binding constant 
Although the iron-binding ligands of the two proteins (transferrin and 
lactoferrin) are the same, there are differences of detail in their iron-binding properties. 
At pH 6.4, human lactoferrin (hLf) binds iron 300 times more strongly than transferrin 
(Tf) at pH 6.7 (Aisen and Leibman, 1972), and while hLf releases Fe3+ over pH range 
4.0 to 2.5, transferrin releases it over the pH range 6.0 to 4.5 (Bullen et al, 1978). 
The binding for both these proteins is represented by the equation 
Because the binding of iron to any of the transferrins is fully reversible, it 
should be possible to determine an equilibrium binding constant. This is complicated, 
however, by the low solubility of Fe3+ in near-neutral solution (10-17M at pH 7.0). 
A method of equilibrium dialysis, using citrate as a competing iron complexing 
agent (Aasa et al, 1963), was used to overcome this low solubility problem, and 
therefore measure the equilibrium constant of the iron transferrin complex. This method 
analyses the amount of iron partitioned between two sides of a membrane with specific-
sized pores. On one side only of the membrane is transferrin. Knowing the total iron 
present, and the amount of free iron (complexed to citrate) on each side, then the 
amount of iron bound to transferrin and hence the equilibrium constant can be 
calculated. Using this method, an equilibrium binding constant for lactoferrin at pH of 
7.4, in air, was calculated to be 4.7 x 1022 M-1 (Harris and Aisen, 1989). 
A.4.3. Anion binding. 
A distinguishing feature of the transferrins is that an anion is bound with each 
metal ion. The anion found in vivo is C032- (or possibly HC03-), although other anions 
than C032- are able to fulfil this role, a common feature of these synergistic anions 
being that they each contain a Lewis base close to a carboxylate group (Schlabach and 
Bates, 1975). Metal ion indicators, EPR experiments, NMR spectroscopy, and X-ray 
crystallography all indicate that the anion is directly attached to the metal ion in the 
transferrins (Harris and Aisen, 1989). 
The ability of transferrin to bind two iron atoms per molecule, and the 
requirement for bicarbonate were first demonstrated by Schade et al (1949). The 
affinity for fe3+ is weak in the absence of an anion (Bates and Schlabach, 1975), and 
that for the anion is weak in the absence of Fe3+. Because of this feature, the 
relationship between the iron and anion is said to be synergistic. 
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A.4.4. Order of binding. 
The next step in understanding the mechanism of iron-binding, was to determine 
the order of events when a transferrin binds iron. Whether metal or anion binding to 
transferrin occurs first is not completely clear, but using 13C-NMR, Zweier et al (1981) 
obseived that anions (oxalate and bicarbonate) bind weakly in the absence of metal ion, 
indicating that anion binding may precede metal binding. 
Kinetic data also suggests that the anion binds first (Kojima and Bates, 1981). 
Using ferric chelate complexes, it has been proposed that there are five steps in the 
formation of the metal-anion-protein complex. These are (i) binding of the anion to the 
apoprotein, (ii) detachment of one or more ligands from the added ferric chelate, (iii) 
formation of a protein-anion-ferric-chelate complex, (iv) loss of the chelate ligand, and 
(v) conformational change involving the closing of the two domains over the ions. The 
closed conformation is locked together by the aspartate ligand, which plays a critical 
role in the metal-bound structure (Anderson et al, 1989). This sequence of events, 
which implies that the initial step involves binding of the anion to its site on the N2 (or 
C2) domain is shown schematically below (Fig A.7). 
+e +O 
Fig. A. 7. A schematic model of the steps involved in the uptake of iron 
by lactoferrin. ( •) Iron; (A) carbonate; Y, Tyr ligands; H, His ligand; 
D, Asp ligand; (0) chelate ligands. (From Baker (1994), with permission). 
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The role of the anion in binding is thought to be twofold. Firstly, it neutralises 
positive charges on the protein in the binding site which may otherwise repel the cation 
(Fe3+), and secondly, by adding two more iron ligands (2 carbonate oxygens), it helps 
form the metal binding-site. 
A.4.5. Other metals. 
While iron (as Fe3+) is bound most strongly to the transferrins, other metal ions 
can also bind to lactoferrin (Ainscough et al, 1980). For one of these, Cu2+, an X-ray 
crystallographic model of the complex with human lactoferrin has been determined 
(Smith et al, 1992). Although this shows a change in metal coordination from 6-
coordinate to 5-coordinate in the N-lobe, the conformation of lactoferrin is still the 
same, suggesting that lactoferrin with metals other than Fe3+ bound, may still bind to 
receptors just as with Fe3+_ 
A.4.6. Iron release. 
In the mid 1970's, it was found that the pH dependence of iron dissociation from 
serum transferrin was biphasic, indicating that there was a difference between the two 
sites. 59Fe3+ was found to be released completely from one site before the other 
(Princiotto and Zapolski, 1975), (Cannon and Chasteen, 1975). The N terminal site is 
acid labile, and the C terminal site is acid stable (Lestas ,1976), so that as the pH of 
human transferrin is lowered, iron is released from the N-lobe (pH 7 to 5.5) before it is 
released from the C-lobe (pH 5.5 to 4). The biphasic acid-induced iron release seen in 
serum transferrin is not seen in lactoferrin, however, in which both sites release iron 
together over the pH range 4.0-2.5. 
The mechanism of iron release for the transferrins is not known, although it is 
thought to involve one or both of the two following proposals. In the first proposal, 
Kretchmar and Raymond (I 986) showed that for serum transferrin iron was lost more 
readily from the N-terminal site and proposed that this may be due to the greater 
flexibility of this lobe. They suggest that conformational changes and electrostatic 
interactions may play a role in iron release. The interdomain interactions at the back of 
the binding pocket are known to differ between transferrin and lactoferrin (Baker and 
Lindley, 1992), and this may account for the difference in the pH at which dissociation 
occurs. 
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The second proposal for iron release in the transferrins suggests that a lowering 
of the pH would cause a protonation of the anion which would either disrupt the 
interaction between the anion and the anion-binding arginine residue (121 in the N-lobe 
of hLf, 465 in the C-lobe), or cause a change in anion coordination to the metal, from 
bidentate to the monodentate, as seen when copper binds to lactoferrin (Smith et al, 
1992). Either mechanism could result in iron release. This second proposal involving 
the protonation of the anion, does not, however, explain why human serum transferrin 
and human lactoferrin release iron at different pH when they both contain the same 
ligands, Fe3+ and anion. Perhaps the environment around the binding site also plays an 
important role in this second scenario by altering the conditions under which 
protonation occurs. 
Studies of half molecule fragments (one lobe only) suggest that the region at the 
back of the iron-binding site is important in iron release. The recombinant N-lobe of 
human lactoferrin differs in this region from the intact molecule, and it releases iron 
over the·pH range 6 to 4.0 (Day et al, 1992). This is higher than that of the complete 
molecule which releases iron between 4.0 and 2.5 (Mazurier and Spik, 1980). 
A.4.7. Differences between the lobes. 
Given the existence of two similar binding sites on transferrins, four forms 
should exist, ie the apo form, two monoferric forms, and the diferric form. The 
existence of monoferric transferrin was first shown by electrophoresis (Aisen et al, 
1966, Wenn and Williams, 1968) and routine separation is now made possible by 
electrophoresis of transferrin partially denatured by 6 M urea at pH 8.4. This method, 
due to Makey and Seal (1976), allows assesment of how much iron is bound to each 
lobe of the molecule under different conditions. 
Using this same method, it was found that in fresh serum, the two sites of 
transferrin are not equally loaded with iron. Initially the N-lobe is preferentially loaded 
with iron, although continued incubation at 370c distributes the iron evenly between 
the lobes. If the serum is stored at -15°C, then iron distribution is directed towards the 
C-lobe (Williams and Moreton, 1980). 
In 1968, fletcher and Huehns ( 1968) suggested that the two sites of iron-binding 
in transferrin may have different roles. They proposed that one site may be involved in 
the iron transport function often assigned to transferrin, while the other site may be 
involved in iron sequestering (antibacterial as for lactoferrin). This was followed by 
kinetic and thermodynamic work by Aisen et al (1978), in which they showed that the 
C terminal site of transferrin binds iron more strongly than the N terminal site. The 
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binding constant was 20 times greater. The release of iron also differed, being faster for 
the N terminal site (which is also more acid-labile, as noted earlier). 
Studies of transferrin-receptor interactions (Bali and Aisen, 1991), show that the 
receptor specifically interacts with the C-lobe of transferrin to release the iron, whereas 
the N-lobe loses iron by a reduction in pH. 
These differences in the two lobes of both human lactoferrin and human serum 
transferrin may be explained by the structure of lactoferrin (Anderson et al, 1990), 
where comparison of apolactoferrin with the iron-bound form shows that there is a 
difference in flexibility between the two lobes. It is thought that the greater flexibility of 
the N-lobe of lactoferrin may help in the binding and release of iron, and this would 
explain the greater thermodynamic stability and slower release of iron from the C-lobe 
compared with the N-lobe (Kretchmar and Raymond, 1986). 
A.5. Conformational chan2es in lactoferrin. 
A.5.1. Domain movements. 
Lactoferrin shares a similar structure, topology, and binding site construction 
with the group II periplasmic binding proteins (Baker et al, 1987) (see Fig A.8). These 
proteins bind and transport small molecules (sugars, anions, amino acids) through the 
periplasmic space of gram negative bacteria, and interact with receptors in the bacterial 
cell wall. The structure of a number have been determined (Quiocho, 1990), and these 
studies show that they have about 300 residues in a two domain structure similar to a 
single lobe of the transferrins. In each domain, helices are packed on either face of a 
central sheet, and two similar extended polypeptides link the domains. Both domains 
provide ligands for the binding site, with one domain providing most of the groups 
thereby serving as the initial site of attachment (as seen in the transferrins). For the 
maltose binding protein (MBP), Spurlino et al (1991) have shown that maltose binds 
first to one domain in the open form. I ., 
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The feature of lactoferrin structure and function that is addressed in this thesis 
involves the conformational change seen in the N-lobe of lactoferrin accompanying 
iron-binding and release. This movement is the largest yet seen in any such protein and 
involves a rigid body rotation of one domain relative to another, through an angle of 
54° (Baker et al, 1991). It enables the protein to move between an open form (in which 
the binding cleft is wide open) and a closed form (in which the domains have closed 
over the bound metal ion). 
Table A.2. lists all the proteins with domain motion for which both open and 
closed forms have been resolved by X-ray crystallography. Table A.3. lists proteins for 
which only one conformation is known, but in which a domain closure mechanism is 
thought to occur. 
Table. A.2. Proteins with a hinge-type mechanism for domain closure 
for which open and closed structures have been determined. 
Lactoferrin Anderson et al, 1990 
Tomato bushy stunt virus coat protein Olson et al, 1983 
Maltodextrin binding protein Sharff et al, 1992 
Lysine-arginine-ornithine binding protein Oh et al, 1993 
T4 lysozyme mutants Faber and Mathews, 1991 
Catabolite gene activator protein 
cAMP dependent protein kinase 
(catalytic domain) 
Adenylate kinase 
Glutamate dehydrogenase 
Calmodulin 
Weber and Steitz, 1987 
Karlsson et al, 1993 
Schulz et al, 1990 
Stillman et al, 1993 
Meador et al, 1992, 1993 
Table. A.3. Proteins with a hinge-type mechanism for which 
only one conformation has been determined. 
Sulfate bindin rotein Luecke and Quiocho, 1990 
rotein Pflu ath and Quiocho, 1988 
Leucine bindin rotein Gilliland and Quiocho, 1981 
Galactose bindin rotein V asetal, 1988, 1991 
Arabinose bindin rotein Sack et al, 1989 
Transferrin Sarra et al, 1990 
Guan late kinase Stehle and Schulz, 1990 
Louie et al, 1992 
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An obvious question concerns why there is such a large domain movement, if 
the function of lactoferrin is only to sequester an atom of iron for bacteriostatic 
purposes. A possible answer for this could be the proposed receptor binding function of 
lactoferrin. Receptor binding is an important feature of the group II periplasmic binding 
proteins (Mowbray, 1992). For these proteins, the large conformational change is 
crucial for signal transduction in active transport (Jacobson et al, 1992), since the 
membrane bound receptors preferentially bind to the liganded, closed form of the 
maltodextrin binding protein (MBP). Furthermore, there are a number of mutations in 
the N and C domains of MBP (corresponding to the Nl and N2 domains of lactoferrin), 
at the opening to the cleft that affect the function of this protein. 
Two of the periplasmic binding proteins have been analysed crystallographically 
in both the open and closed forms, ie the maltodextrin binding protein (Spurlino et al, 
1991, Sharff et al, 1992), and the lysine-arginine-omithine (LAO) binding protein (Oh 
et al, 1993). The nature of the domain movement is similar to that of lactoferrin. MBP 
has a 35° rotation of one domain relative to the other about an axis through the hinge 
region, while for LAOBP a movement of 52°, similar to that in the N-lobe of .1 
lactoferrin, is seen. This motion, as for lactoferrin (see below), involves only a few 
large torsion angle changes. In addition, two of the periplasmic binding proteins bind 
anions in a similar way to lactoferrin, ie the sulphate binding protein (Pflugrath and 
Quiocho, 1988), and the phosphate binding protein (Luecke and Quiocho, 1990). These 
two proteins have a similar fold to a single lobe of lactoferrin, and their anion binding 
sites coincide with the carbonate site in the transferrins. What is interesting is that there 
is a greater sequence similarity between the sulphate binding protein and lactoferrin 
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(15%), than between the sulphate and phosphate binding proteins (<10%) (Baker, 
1994). 
a b 
Fig. A.8. Comparison of the folding pattern for the N-lobe of lactoferrin (a) 
and for the sulphate binding protein (b). (From Baker (1994), with permission). 
A.5.2. The hinge of lactof err in. 
The large rigid body motion in lactoferrin is made possible by two extended 
polypeptide strands that run behind the binding cleft connecting the two domains of 
each lobe. 
In Fig A.9, the hinges in the N-lobe of human lactoferrin are indicated. Gerstein 
et al (1993) described the motion as a screw motion by fixing the origin so that 
translation was minimal upon domain movement. In this description, the N2 domain 
translates only LOA with the rotation axis passing very close to Tor 90 and Pro 251, the 
two residues Anderson et al (1990) identified as the centre of the hinges; the axis is 
within 1.4A of the Ca. of the Thr 90, and 2.4A of the Ccx of Pro 251. Therefore the 
motion of N2 relative to NI involves almost no translation, and is instead a pure 
rotation about the central residue in each hinge (fhr 90 and Pro 251). This is illustrated 
in Fig. A.10. 
Fig. A.9. Polypeptide folding pattern for the N-lobe of lactoferrin 
indicating the two beta strands responsible for the position of 
the hinge. (From Baker (1994), with permission) . 
Fig. A.10. Mai n chain atoms only of the open (red) and closed (blue) structures 
of the two beta strands involved in the hinge of lactoferrin. 
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In the first hinge, the domain movement is associated with torsion angle changes 
in 'I' (90) and <I> (91), these changes being coupled across a peptide bond (Fig A. 11). In 
total these produce a rotation of 81 ° , which, although greater than the overall 54° 
rotation seen in the N-lobe, is compensated by small opposing changes in the torsions 
of neighbouring residues (Gerstein et al, 1993). 
",N-c • 
2 HIS 91 
ARG 89 
Fig. A. I 1. Residues 89 - 92 of the first beta strand involved in the hinge 
motion of the N-lobe of lactoferrin. The phi and psi angles 
responsible for the motion are indicated. 
The second hinge is not so simple. Three torsion angles have changes greater 
that 200; ie <I> (250), 'I' (250), and <I> (251), with the central angle('!' (250)) changing by 
33 degrees. These angles are also coupled across a peptide bond to produce a rotation of 
49o (Fig A.12). 
Fig. A.12. Residues 250 - 25 3 of the second beta strand involved in the 
hinge motion of the N-lobe of lactofenin. The phi and psi angles 
involved in the motion are indicated. 
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The axis of the overall 54° rotation is closely aligned with the rotational axis of 
these principal torsion angle changes. This means that the local motion of the hinge 
reflects the overall domain movement of the molecule. 
The principal torsion angle changes in the lactoferrin hinge occur in normally 
allowed regions of the Ramachandran plot (Fig A.13) and therefore involve only low 
energy transitions, indicating that the open and closed states can occur in dynamic 
equilibrium as proposed for the periplasmic binding proteins (Oh et al, 1993). 
H91 
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0 180 
<l> 
Fig. A.13. Ramachandran plot of the main chain torsion angle changes 
seen in the N-lobe of lactoferrin. Phi and psi angles are shown with 
open circles for the open conformation, and with filled circles for the 
closed conformation. 
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In the ribose and galactose binding proteins however, there is a residue (215 in 
RBP, 236 in GBP) that has an unfavourable conformation. This is one of only two 
Ramachandran violations in these proteins, and the conformation is necessary for the 
correct action of the hinge in these proteins (Mowbray, 1992). A buried aspanate helps 
maintain this conformation and therefore the correct action of the hinge. In human 
lactof errin, the one Ramachandran violation is not associated with the hinges. 
The location of the hinges with respect to the ligands seems likely to be 
important in lactoferrin. Tyr 92 (a ligand) is 2 residues away from Tor 90 (human 
lactoferrin numbering), and His 253 is two residues away from Pro 251. This allows the 
hinges to split these two ligands, with Tyr 92 moving with the N2 domain, and His 253 
with the Nl domain. This provides the N2 domain with 4 of the 6 iron-binding groups 
(2 from the carbonate anion together with Tyr 92 and Tyr 192). The N2 domain is 
thought to serve as the initial site of attachment. This is supported by recent work by 
Lindley et al (1993) on the analysis of a proteolytic fragment of duck ovotransferrin 
corresponding to its N2 domain. In this one-domain molecule, the iron is bound to the 
carbonate ion and to two tyrosine residues just as in the intact molecule. Presumably 
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once the iron is bound to the N2 domain, domain closure occurs to allow the iron to 
complete its coordination to His 253 and Asp 60, and the aspartate helps lock the two 
domains together with an interdomain hydrogen bond (Anderson et al, 1989). 
It has been proposed that the apo-protein is in a dynamic equilibrium, with the 
Nl and N2 domains "flexing" about the hinge, and that the iron then stabilises the 
closed form as the bound ligand does in the periplasmic binding proteins. The 
importance of the hinge in this mechanism woulq be in directing the two domains 
together into the correct position by restraining the number of conformations in the 
open state. 
In most proteins, the main chain is buried beneath layers of side chains leaving 
little freedom for large torsion angle changes. In the hinge region of 
lactoferrin,however, the main chain is free from steric constraint, with the mainchain 
atoms of Thr 90, His 91, and Pro 251 making no contacts with the rest of the protein. 
The absence of main chain packing constraints with the rest of the protein, and the 
absence of internal hydrogen bonds is also found in hinged mechanisms in lactate 
dehydrogenase (Gerstein and Chothia, 1991) and in adenylate kinase (Gerstein et al, 
1993) and appears to be a crucial structural requirement for hinged motion. 
A.5.3. Amino acid sequences in the hinges. 
The sequences of the hinge regions in transferrins are listed in Table A.4. and 
Table A.5. and display a remarkable degree of sequence conservation. 
In the N-lobe, the hinges are located at Tor 90 in one "backbone" strand and Pro 
251 in the other. Elsewhere in the two strands, a number of residues are conserved 
either because they are ligands (Tyr 92 and His 253) or because they contribute to the 
hydrophobic core of one domain or the other (the sequences AV A VV in the first strand, 
and A VV in the second strand). The most intriguing conservation, however, is that of 
Tor 90 and Pro 251. 
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Table A.4. Amino acid sequence in the two hinge strands of the N-tenninal lobe, 
for all known transferrin sequence. 
Human Serotransferrin EDPQTFYYAVAVVKK HLAQVPSHTVVAR 
Horse Serotransferrin TEPQTHYYAVAVVKK YLAS IP SHA VVAR 
Pig Serotransferrin DNPGTHYYAVAVVKK YLAQVP SHA VVAR 
Rabbit Serotransferrin ENPKTFYYAVALVKK HLARVPSHAVVAR 
Rat Serotransferrin EHRQTHYLAVAVVKK YLARIPSHAVVAR 
Xenopus Serotransf errin TETDTCYYAVAVVKK NLAKVPAHAVLTR 
Human Lactoferrin RQPRTHYYAVAVVKK HLARVP SHAVVAR 
Bovine Lactoferrin ESPQTHYYAVAVVKK HLAQVP SHA VVAR 
Goat Lactoferrin KSPQTHYYAVAVVKK HLAQVP SHAVVAR 
Mouse Lactof errin EQPRTHYYAVAVVKN HLAQVPSHAVVSR 
Pig Lactoferrin ENPGTYYYAVAVVKK HLARVP SHA VVAR 
Human Melanotransferrin QEVGTSYYAVAVVFR HLARVP AHA VVVR 
Chicken Ovotransf errin EGSTTSYYAVAVVKK NWARVAAHAVVAR 
Atlantic Salmon Transferri EDSDTCYYAVAVAKK HLARVP AHA VVSR 
Hornworm Transferrin PDAPFRYEAVIVVHK SWAARPWQGLIGH 
Cockroach Transferrin PDEEFRYEAVCVIHK IWAARPW GYMAN 
11rr 90 is totally conserved, except in the two insect transferrins. It is difficult to 
see why this should be so unless this residue is important for the function of transferrins 
in general. The obvious conclusion is that Thr 90 has some as yet unsuspected role in 
helping to define the conformational change, since it is at the exact location of one of 
the hinges. The only apparent interaction made by the sidechain of Tor 90 is a hydrogen 
bond with the C-terminal helix of the full-length molecule (90 OGl - O=C 691), this 
being present in apolactoferrin but not in Fe2Lf. 
Pro 251 is also totally conserved, except in chicken ovotransferrin. Proline 
residues are known for their restraining role in the polypeptide conformation, and are 
present in the hinge regions of several bacterial binding proteins where their presence 
may modulate the motion of the hinge (Mowbray ,1992). 
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Table A.5. Amino acid sequence of the two hinge strands of the 
C-terminal lobe, for all known transferrin sequences. 
Human Serotransferrin DTPEAGYFAVAVVKK HLAMAPNHAWSR 
Horse Serotransferrin DTPEEGYHAVAVVKS YLARAPNHAWSR 
Pig Serotransferrin NTPEKGYLAVAVVKK HLARAPNHAWAR 
Rabbit Serotransferrin KAPEEGYLSVAVVKK HLAKAPNHAWSR 
Rat Serotransferrin QSDVFPKGYYAVAW HLAQAPNHWVSR 
Xenopus Serotransferrin SQAKGNYYAVAIVKK NLAEVP AHAVVTL 
Human Lactoferrin DRPVEGYLAVAWRR HLAMAPNHAWSR 
Bovine Lactoferrin LRPTEGYLAVAVVKK HLAVAPNHAWSR 
Goat Lactoferrin LRPTEGYLAVAVVKK YLAVAPNHAWSR 
Mouse Lactoferrin NRPVEGYLAVAAVRR HLAIAPNHAWSR 
Pig Lactoferrin HRPTGGYFAVAWRK HLAVAPSHAWSR 
Human Melanotransferrin EDSSNSYYWAWRR NLAQIPPHAVMVR 
Chicken Ovotransferrin ERPA SYFAVAVARK NLAEVPTHAWVR 
Atlantic Salmon Transferri PGEASSYYAVAVAKK HLAKVPAHAVITR 
Homworm Transferrin GELKTPNYAVAVVKK 
Cockroach Transferrin GEHGSLYYAVAWRK 
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In the C-lobe there is no conserved residue equivalent to Tor 90 in the first 
strand, although there is a totally conserved proline equivalent to Pro 251 in the second 
strand. In the C-lobe, however, the exact location of the hinge is not yet known. 
Oh et al (1993) have suggested that the residues in the hinge do not play any 
pan in the domain movement. The conservation of hinge residues seen in lactoferrin 
sequences argues against this view, however. In order to test this apparent 
contradiction, an obvious approach is to mutate the two conserved residues in the hinge 
(Thr 90 and Pro 251) and to characterise the resulting proteins by iron-binding studies 
and x-ray crystallography. 
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A.6. Aims of this proiect. 
The aims of this project were to address the roles of the two "hinge" residues, 
Tor 90 and Pro 251, by site-directed mutagenesis and characterisation of the resultant 
mutant proteins. 
The cDNA from human lactoferrin had previously been cloned into a suitable 
expression vector and expression had been shown to occur (Day, 1993). The complete 
structure for the half-length molecule had been solved by molecular replacement by 
Day (1993) using the Fe2Lf structure as a starting model (Anderson et al, 1989). Bates 
(1994) had also cloned a segment of the human lactoferrin cDNA encoding amino acids 
250 to 688 into the M 13 bacteriophage. 
In order to introduce amino acid changes into the cDNA for human lactoferrin, 
the method of Kunkel (1989) was chosen. Changes made in the M 13 bacteriophage 
containing this segment were to be cloned into the pNUT vector containing the half-
length lactoferrin cDNA (pNUT:LfN) consrructed by Day (1993). This would then be 
used in tissue culture to produce the recombinant proteins. After purification of the 
recombinant protein, their iron-release properties would be examined, and the structural 
effects of mutation determined by x-ray crystallography. 
The changes at Pro 251 were designed to allow varying degrees of flexibility 
into this region. For this reason, Gly, Ala and Val were chosen. Asp was also chosen as 
this is convenient using a degenerate oligonucleotide, and this change also introduces a 
negative charge into this region. 
The changes at Thr 90 involved a change to alanine in order to determine the 
imponance of the proposed hydrogen bond between the side chain hydroxyl group of 
Tor 90 and C-terminal end of the polypeptide chain. 
